HIV-associated dementia in the era of highly active antiretroviral therapy (HAART)

Microbes and Infection

Volumn 13, Issue 5, 2011, Pages 419-425

  Xia, Chenglai ^a,b   Luo, Dixian ^c   Yu, Xiaoling ^b   Jiang, Shibo ^b,d   Liu, Shuwen ^b  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF SOUTH CHINA   (China)

^d NEW YORK BLOOD CENTER   (United States)

Author keywords

Encephalopathy; HIV associated dementia; Human immunodeficiency virus

Indexed keywords

4 AMINOPYRIDINE; ANTIOXIDANT; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN E; EFAVIRENZ; EMTRICITABINE; GLYCOPROTEIN GP 120; LAMIVUDINE; LOPINAVIR; MONOAMINE OXIDASE B INHIBITOR; RITONAVIR; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BEHAVIOR DISORDER; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; COGNITIVE DEFECT; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MOTOR DYSFUNCTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SHORT SURVEY; VIRUS LOAD;

AIDS DEMENTIA COMPLEX; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-1; HUMANS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79953267874     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2011.01.004     Document Type: Short Survey

References (52)

1. Kaushik-Basu N., Basu A., Harris D. Peptide inhibition of HIV-1: current status and future potential. BioDrugs 2008, 22:161-175.
2. Cai L., Jiang S. Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41. ChemMedChem. 2010, 5:1813-1824.
3. Zhou L., Rua R., Ng T., Vongrad V., Ho Y.S., Geczy C., Hsu K., Brew B.J., Saksena N.K. Evidence for predilection of macrophage infiltration patterns in the deeper midline and mesial temporal structures of the brain uniquely in patients with HIV-associated dementia. BMC Infect. Dis. 2009, 9:192.
4. Streit W.J., Miller K.R., Lopes K.O., Njie E. Microglial degeneration in the aging brain-bad news for neurons?. Front. Biosci. 2008, 13:3423-3438.
5. Gras G., Kaul M. Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection. Retrovirology 2010, 7:30.
6. Rawat D., Capoor M.R., Nair D., Deb M., Aggarwal P. Concomitant TB and cryptococcosis in HIV-infected patients. Trop. Doct. 2008, 38:251-252.
7. Bhaskaran K., Mussini C., Antinori A., Walker A.S., Dorrucci M., Sabin C., Phillips A., Porter K. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann. Neurol. 2008, 63:213-221.
8. Wu Y.C., Zhao Y.B., Tang M.G., Zhang-Nunes S.X., McArthur J.C. AIDS dementia complex in China. J. Clin. Neurosci. 2007, 14:8-11.
9. Ances B.M., Ellis R.J. Dementia and neurocognitive disorders due to HIV-1 infection. Semin. Neurol. 2007, 27:86-92.
10. Bottiggi K.A., Chang J.J., Schmitt F.A., Avison M.J., Mootoor Y., Nath A., Berger J.R. The HIV dementia scale: predictive power in mild dementia and HAART. J. Neurol. Sci. 2007, 260:11-15.
11. Tozzi V., Balestra P., Bellagamba R., Corpolongo A., Salvatori M.F., Visco-Comandini U., Vlassi C., Giulianelli M., Galgani S., Antinori A., Narciso P. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J. Acquir. Immune. Defic. Syndr. 2007, 45:174-182.
12. Kipnis J., Derecki N.C., Yang C., Scrable H. Immunity and cognition: what do age-related dementia, HIV-dementia and 'chemo-brain' have in common?. Trends Immunol. 2008, 29:455-463.
13. Fischer-Smith T., Rappaport J. Evolving paradigms in the pathogenesis of HIV-1-associated dementia. Expert Rev. Mol. Med. 2005, 7:1-26.
14. Yadav A., Collman R.G. CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. J. Neuroimmune. Pharmacol. 2009, 4:430-447.
15. Medders K.E., Sejbuk N.E., Maung R., Desai M.K., Kaul M. Activation of p38 MAPK is required in monocytic and neuronal cells for HIV glycoprotein 120-induced neurotoxicity. J. Immunol. 2010, 185:4883-4895.
16. Mohamed M.A., Lentz M.R., Lee V., Halpern E.F., Sacktor N., Selnes O., Barker P.B., Pomper M.G. Factor analysis of proton MR spectroscopic imaging data in HIV infection: metabolite-derived factors help identify infection and dementia. Radiology 2010, 254:577-586.
17. Kou W., Banerjee S., Eudy J., Smith L.M., Persidsky R., Borgmann K., Wu L., Sakhuja N., Deshpande M.S., Walseth T.F., Ghorpade A. CD38 regulation in activated astrocytes: implications for neuroinflammation and HIV-1 brain infection. J. Neurosci. Res. 2009, 87:2326-2339.
18. Zhao M.L., Si Q., Lee S.C. IL-16 expression in lymphocytes and microglia in HIV-1 encephalitis. Neuropathol. Appl. Neurobiol. 2004, 30:233-242.
19. Butovsky O., Talpalar A.E., Ben-Yaakov K., Schwartz M. Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. Mol. Cell Neurosci. 2005, 29:381-393.
20. Thomas E.R., Dunfee R.L., Stanton J., Bogdan D., Kunstman K., Wolinsky S.M., Gabuzda D. High frequency of defective vpu compared with tat and rev genes in brain from patients with HIV type 1-associated dementia, AIDS. Res. Hum. Retroviruses. 2007, 23:575-580.
21. Dhillon N.K., Peng F., Ransohoff R.M., Buch S. PDGF synergistically enhances IFN-gamma-induced expression of CXCL10 in blood-derived macrophages: implications for HIV dementia. J. Immunol. 2007, 179:2722-2730.
22. Giunta B., Obregon D., Hou H., Zeng J., Sun N., Nikolic V., Ehrhart J., Shytle D., Fernandez F., Tan J. EGCG mitigates neurotoxicity mediated by HIV-1 proteins gp120 and Tat in the presence of IFN-gamma: role of JAK/STAT1 signaling and implications for HIV-associated dementia. Brain Res. 2006, 1123:216-225.
23. Letendre S.L., Ellis R.J., Ances B.M., McCutchan J.A. Neurologic complications of HIV disease and their treatment. Top. HIV Med. 2010, 18:45-55.
24. Hahn Y.K., Vo P., Fitting S., Block M.L., Hauser K.F., Knapp P.E. Beta-chemokine production by neural and glial progenitor cells is enhanced by HIV-1 tat: effects on microglial migration. J. Neurochem. 2010, 114:97-109.
25. Kaul M. HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches. Curr. Opin. Neurol. 2009, 22:315-320.
26. Ragin A.B., Wu Y., Storey P., Cohen B.A., Edelman R.R., Epstein L.G. Monocyte chemoattractant protein-1 correlates with subcortical brain injury in HIV infection. Neurology 2006, 66:1255-1257.
27. Dhillon N.K., Williams R., Callen S., Zien C., Narayan O., Buch S. Roles of MCP-1 in development of HIV-dementia. Front. Biosci. 2008, 13:3913-3918.
28. Pemberton L.A., Stone E., Price P., van Bockxmeer F., Brew B.J. The relationship between ApoE, TNFA, IL1a, IL1b and IL12b genes and HIV-1-associated dementia. HIV Med. 2008, 9:677-680.
29. Pomara N., Belzer K., Sidtis J.J. Deleterious CNS effects of the APOE epsilon4 allele in individuals with HIV-1 infection may be age-dependent. Proc. Natl. Acad. Sci. U. S. A. 2008, 105. E65, E67-E68.
30. Cutler R.G., Haughey N.J., Tammara A., McArthur J.C., Nath A., Reid R., Vargas D.L., Pardo C.A., Mattson M.P. Dysregulation of sphingolipid and sterol metabolism by ApoE4 in HIV dementia. Neurology. 2004, 63:626-630.
31. Hayashi H., Campenot R.B., Vance D.E., Vance J.E. Apolipoprotein E-containing lipoproteins protect neurons from apoptosis via a signaling pathway involving low-density lipoprotein receptor-related protein-1. J. Neurosci. 2007, 27:1933-1941.
32. Jiang Q., Lee C.Y., Mandrekar S., Wilkinson B., Cramer P., Zelcer N., Mann K., Lamb B., Willson T.M., Collins J.L., Richardson J.C., Smith J.D., Comery T.A., Riddell D., Holtzman D.M., Tontonoz P., Landreth G.E. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008, 58:681-693.
33. Kitagawa K., Matsumoto M., Hori M., Yanagihara T. Neuroprotective effect of apolipoprotein E against ischemia. Ann. N. Y. Acad. Sci. 2002, 977:468-475.
34. van Meer P., Acevedo S., Raber J. Impairments in spatial memory retention of GFAP-apoE4 female mice. Behav. Brain Res. 2007, 176:372-375.
35. Vitek M.P., Brown C.M., Colton C.A. APOE genotype-specific differences in the innate immune response. Neurobiol. Aging. 2009, 30:1350-1360.
36. Pocernich C.B., Sultana R., Hone E., Turchan J., Martins R.N., Calabrese V., Nath A., Butterfield D.A. Effects of apolipoprotein E on the human immunodeficiency virus protein tat in neuronal cultures and synaptosomes. J. Neurosci. Res. 2004, 77:532-539.
37. Burt T.D., Agan B.K., Marconi V.C., He W., Kulkarni H., Mold J.E., Cavrois M., Huang Y., Mahley R.W., Dolan M.J., McCune J.M., Ahuja S.K. Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. Proc. Natl. Acad. Sci. U. S. A 2008, 105:8718-8723.
38. Zhou L., Wang X., Wang Y.J., Zhou Y., Hu S., Ye L., Hou W., Li H., Ho W.Z. Activation of toll-like receptor-3 induces interferon-lambda expression in human neuronal cells. Neuroscience. 2009, 159:629-637.
39. Wang Y.J., Wang X., Zhang H., Zhou L., Liu S., Kolson D.L., Song L., Ye L., Ho W.Z. Expression and regulation of antiviral protein APOBEC3G in human neuronal cells. J. Neuroimmunol. 2009, 206:14-21.
40. Zhao L., Galligan D.C., Lamers S.L., Yu S., Shagrun L., Salemi M., McGrath M.S. High level HIV-1 DNA concentrations in brain tissues differentiate patients with post-HAART AIDS dementia complex or cardiovascular disease from those with AIDS. Sci. China C. Life Sci. 2009, 52:651-656.
41. Brew B.J. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 2004, 18(Suppl 1):S75-S78.
42. Kraft-Terry S., Gerena Y., Wojna V., Plaud-Valentin M., Rodriguez Y., Ciborowski P., Mayo R., Skolasky R., Gendelman H.E., Melendez L.M. Proteomic analyses of monocytes obtained from hispanic women with HIV-associated dementia show depressed antioxidants. Proteomics Clin. Appl. 2010, 4:706-714.
43. Douvoyiannis M., Litman N. Acute encephalopathy and multi-organ involvement with rhabdomyolysis during primary HIV infection. Int. J. Infect. Dis. 2009, 13:e299-e304.
44. Price R.W., Epstein L.G., Becker J.T., Cinque P., Gisslen M., Pulliam L., McArthur J.C. Biomarkers of HIV-1 CNS infection and injury. Neurology. 2007, 69:1781-1788.
45. Keller M.A., Venkatraman T.N., Thomas M.A., Deveikis A., Lopresti C., Hayes J., Berman N., Walot I., Ernst T., Chang L. Cerebral metabolites in HIV-infected children followed for 10 months with 1H-MRS. Neurology 2006, 66:874-879.
46. Jevtovic D., Vanovac V., Veselinovic M., Salemovic D., Ranin J., Stefanova E. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART. Biomed. Pharmacother. 2009, 63:561-565.
47. Brouwer A.E., Teparrukkul P., Rajanuwong A., Chierakul W., Mahavanakul W., Chantratita W., White N.J., Harrison T.S. Cerebrospinal fluid HIV-1 viral load during treatment of cryptococcal meningitis. J. Acquir. Immune. Defic. Syndr. 2010, 53:668-669.
48. Zink M.C., Uhrlaub J., DeWitt J., Voelker T., Bullock B., Mankowski J., Tarwater P., Clements J., Barber S. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 2005, 293:2003-2011.
49. Keblesh J.P., Dou H., Gendelman H.E., Xiong H. 4-Aminopyridine improves spatial memory in a murine model of HIV-1 encephalitis. J. Neuroimmune. Pharmacol. 2009, 4:317-327.
50. Tang H., Lu D., Pan R., Qin X., Xiong H., Dong J. Curcumin improves spatial memory impairment induced by human immunodeficiency virus type 1 glycoprotein 120 V3 loop peptide in rats. Life Sci. 2009, 85:1-10.
51. Schifitto G., Zhang J., Evans S.R., Sacktor N., Simpson D., Millar L.L., Hung V.L., Miller E.N., Smith E., Ellis R.J., Valcour V., Singer E., Marra C.M., Kolson D., Weihe J., Remmel R., Katzenstein D., Clifford D.B. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology. 2007, 69:1314-1321.
52. Velazquez I., Plaud M., Wojna V., Skolasky R., Laspiur J.P., Melendez L.M. Antioxidant enzyme dysfunction in monocytes and CSF of Hispanic women with HIV-associated cognitive impairment. J. Neuroimmunol. 2009, 206:106-111.